
**Cardiovascular implants — Cardiac
valve prostheses —**

**Part 3:
Heart valve substitutes implanted by
transcatheter techniques**

Implants cardiovasculaires — Prothèses valvulaires —

*Partie 3: Valves cardiaques de substitution implantées par des
techniques transcathéter*



This document is a preview generated by EBS



COPYRIGHT PROTECTED DOCUMENT

© ISO 2013

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

| | Page |
|--|------|
| Foreword..... | v |
| Introduction..... | vi |
| 1 Scope..... | 1 |
| 2 Normative references..... | 1 |
| 3 Terms and definitions..... | 2 |
| 4 Abbreviations..... | 10 |
| 5 Fundamental requirements..... | 10 |
| 6 Device description..... | 10 |
| 6.1 Intended use..... | 10 |
| 6.2 Design inputs..... | 10 |
| 6.3 Design outputs..... | 13 |
| 6.4 Design transfer (manufacturing verification/validation)..... | 13 |
| 6.5 Risk management..... | 14 |
| 7 Design verification testing and analysis/design validation..... | 14 |
| 7.1 General requirements..... | 14 |
| 7.2 <i>In vitro</i> assessment..... | 14 |
| 7.3 Preclinical <i>in vivo</i> evaluation..... | 23 |
| 7.4 Clinical investigations..... | 26 |
| Annex A (informative) Rationale for the provisions of this part of ISO 5840..... | 31 |
| Annex B (informative) Examples of transcatheter heart valve substitutes, components and delivery systems..... | 34 |
| Annex C (normative) Packaging..... | 40 |
| Annex D (normative) Product labels, instructions for use and training..... | 41 |
| Annex E (normative) Sterilization..... | 44 |
| Annex F (informative) Valve description..... | 45 |
| Annex G (informative) Transcatheter heart valve substitute hazards, associated failure modes and evaluation methods..... | 47 |
| Annex H (informative) <i>In vitro</i> test guidelines for paediatric devices..... | 51 |
| Annex I (informative) Statistical procedures when using performance criteria..... | 55 |
| Annex J (informative) Examples and definitions of some physical and material properties of transcatheter heart valve substitutes and their components..... | 56 |
| Annex K (informative) Examples of standards applicable to testing of materials and components of transcatheter heart valve substitutes..... | 69 |
| Annex L (informative) Raw and post-conditioning mechanical properties for support structure materials..... | 75 |
| Annex M (informative) Corrosion assessment..... | 77 |
| Annex N (informative) Guidelines for verification of hydrodynamic performance..... | 80 |
| Annex O (informative) Durability testing..... | 84 |
| Annex P (informative) Fatigue assessment..... | 86 |
| Annex Q (informative) Preclinical <i>in vivo</i> evaluation..... | 92 |
| Annex R (normative) Adverse event classification during clinical investigation..... | 95 |
| Annex S (informative) Echocardiographic protocol..... | 100 |

| | |
|---------------------------|------------|
| Bibliography | 103 |
|---------------------------|------------|

This document is a preview generated by EVS

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 5840-3 was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

ISO 5840 consists of the following parts, under the general title *Cardiovascular implants — Cardiac valve prostheses*:

— *Part 3: Heart valve substitutes implanted by minimally invasive techniques*

Introduction

No heart valve substitute is ideal. Therefore, a group of engineers, scientists and clinicians well aware of the problems associated with heart valve substitutes and their development has prepared this part of ISO 5840. In several areas, the provisions of this part of ISO 5840 have been deliberately left partially defined so as not to inhibit development and innovation. This part of ISO 5840 specifies types of tests, test methods and requirements for test apparatus. It requires documentation of test methods and results. This part of ISO 5840 deals with those areas that will ensure adequate mitigation of device-associated risks for patients and other users of the device, facilitate quality assurance, aid the cardiac surgeon and cardiologist in choosing a heart valve substitute, and ensure that the device will be presented in a convenient form. This part of ISO 5840 emphasizes the need to specify types of *in vitro* testing, preclinical *in vivo* and clinical evaluations as well as to report all *in vitro*, preclinical *in vivo* and clinical evaluations. It describes the labels and packaging of the device. Such a process involving *in vitro*, preclinical *in vivo* and clinical evaluations is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent problems.

With regard to *in vitro* testing and reporting, apart from basic material testing for mechanical, physical, chemical and biocompatibility characteristics, this part of ISO 5840 also covers important hydrodynamic and durability characteristics of transcatheter heart valve substitutes and their delivery systems. This part of ISO 5840 does not specify exact test methods for hydrodynamic and durability testing but it offers guidelines for the test apparatus.

This part of ISO 5840 should be revised, updated and amended as knowledge and techniques in heart valve substitute technology improve.

This part of ISO 5840 is to be used in conjunction with ISO 5840:2005, which will be replaced by ISO 5840-1 in future.

Cardiovascular implants — Cardiac valve prostheses —

Part 3: Heart valve substitutes implanted by transcatheter techniques

1 Scope

This part of ISO 5840 outlines an approach for verifying/validating the design and manufacture of a transcatheter heart valve substitute through risk management. The selection of appropriate verification/validation tests and methods are to be derived from the risk assessment. The tests may include those to assess the physical, chemical, biological and mechanical properties of heart valve substitutes and of their materials and components. The tests can also include those for preclinical *in vivo* evaluation and clinical evaluation of the finished heart valve substitute.

This part of ISO 5840 defines operational conditions and performance requirements for transcatheter heart valve substitutes where adequate scientific and/or clinical evidence exists for their justification.

This part of ISO 5840 is applicable to all devices intended for implantation in human hearts as a transcatheter heart valve substitute.

This part of ISO 5840 is applicable to both newly developed and modified transcatheter heart valve substitutes and to the accessory devices, packaging and labelling required for their implantation and for determining the appropriate size of heart valve substitute to be implanted.

This part of ISO 5840 excludes heart valve substitutes designed for implantation in artificial hearts or heart assist devices.

This part of ISO 5840 excludes valve-in-valve configurations and homografts.

This part of ISO 5840 does not specifically address non-traditional surgically implanted heart valve substitutes (e.g. sutureless). For these devices, the requirements of both this part of ISO 5840 and ISO 5840:2005 might be relevant and can be considered.

NOTE A rationale for the provisions of this part of ISO 5840 is given in [Annex A](#).

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 11135-1, *Sterilization of health care products — Ethylene oxide — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO/TS 11135-2, *Sterilization of health care products — Ethylene oxide — Part 2: Guidance on the application of ISO 11135-1*